Company’s 36-month beta value is 1.72.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CYCN is 1.96M, and currently, short sellers hold a 4.33% ratio of that floaft. The average trading volume of CYCN on January 15, 2025 was 3.18M shares.
CYCN) stock’s latest price update
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has experienced a decline in its stock price by -9.60 compared to its previous closing price of 3.23. However, the company has seen a fall of -7.01% in its stock price over the last five trading days. globenewswire.com reported 2024-12-17 that CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth.
CYCN’s Market Performance
Cyclerion Therapeutics Inc (CYCN) has seen a -7.01% fall in stock performance for the week, with a -21.08% decline in the past month and a 14.55% surge in the past quarter. The volatility ratio for the week is 10.37%, and the volatility levels for the past 30 days are at 12.77% for CYCN. The simple moving average for the past 20 days is -9.58% for CYCN’s stock, with a 1.16% simple moving average for the past 200 days.
Analysts’ Opinion of CYCN
Many brokerage firms have already submitted their reports for CYCN stocks, with Truist repeating the rating for CYCN by listing it as a “Buy.” The predicted price for CYCN in the upcoming period, according to Truist is $14 based on the research report published on October 20, 2021 of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see CYCN reach a price target of $7. The rating they have provided for CYCN stocks is “Overweight” according to the report published on September 24th, 2021.
CYCN Trading at 0.84% from the 50-Day Moving Average
After a stumble in the market that brought CYCN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.17% of loss for the given period.
Volatility was left at 12.77%, however, over the last 30 days, the volatility rate increased by 10.37%, as shares sank -18.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.67% lower at present.
During the last 5 trading sessions, CYCN fell by -7.01%, which changed the moving average for the period of 200-days by -2.67% in comparison to the 20-day moving average, which settled at $3.23. In addition, Cyclerion Therapeutics Inc saw -9.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCN starting from Slate Path Capital LP, who sale 357,880 shares at the price of $1.55 back on Nov 21 ’24. After this action, Slate Path Capital LP now owns 0 shares of Cyclerion Therapeutics Inc, valued at $555,108 using the latest closing price.
Stock Fundamentals for CYCN
Current profitability levels for the company are sitting at:
- -30.54 for the present operating margin
- 1.0 for the gross margin
The net margin for Cyclerion Therapeutics Inc stands at -27.22. The total capital return value is set at -0.72. Equity return is now at value -50.13, with -43.80 for asset returns.
Currently, EBITDA for the company is -12.59 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 25.99. The receivables turnover for the company is 4.41for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.07.
Conclusion
In a nutshell, Cyclerion Therapeutics Inc (CYCN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
